FirstWord Pharma (@fwpharma) header
FirstWord Pharma (@fwpharma) profile picture

FirstWord Pharma

@fwpharma

The latest global #pharma news, insights, analysis, and views providing you with an information edge. FirstWord Pharma. Where people who know first, go first.

firstwordpharma.com
Joined April 2009
  • Tweets40.9K
  • Following586
  • Followers55.3K
1.5KMedia
Photo by FirstWord Pharma (@fwpharma)Photo by FirstWord Pharma (@fwpharma)Photo by FirstWord Pharma (@fwpharma)Photo by FirstWord Pharma (@fwpharma)Photo by FirstWord Pharma (@fwpharma)Photo by FirstWord Pharma (@fwpharma)Photo by FirstWord Pharma (@fwpharma)Photo by FirstWord Pharma (@fwpharma)Photo by FirstWord Pharma (@fwpharma)Photo by FirstWord Pharma (@fwpharma)
Gilead's third-quarter HIV sales push growth to highest levels in over a decade $GILD firstwordpharma.com/story/83…
203
BioMarin licenses Fabry disease hopeful in $475M deal with GC Biopharma, Hanmi $BMRN firstwordpharma.com/story/83…
4
665
Flagship meshes three startups to form AI-powered drug discovery firm Etcelera firstwordpharma.com/story/83…
1
3
425
BMS gets boost from older drug Eliquis in Q3, but Opdivo comes up short $BMY firstwordpharma.com/story/83…
2
761
Lilly jacks up outlook as CFO says it's 'scratching the surface' of incretin market $LLY firstwordpharma.com/story/83…
3
680
Dren Bio pulls in $350M to steer lead blood cancer drug to market firstwordpharma.com/story/83…
Dren Bio pulls in $350M to steer lead blood cancer drug to market

Dren Bio pulls in $350M to steer lead blood cancer drug to market

Dren Bio closed a $350-million private financing as the biotech looks to speed ...

firstwordpharma.com
1
1
971
Merck & Co. tops estimates as Keytruda, Gardasil, Winrevair all outperform in Q3 $MRK firstwordpharma.com/story/83…
Merck & Co. tops estimates as Keytruda, Gardasil, Winrevair all outperform in Q3

Merck & Co. tops estimates as Keytruda, Gardasil, Winrevair all outperform in Q3

Merck & Co. on Thursday reported that third-quarter revenue grew 5% year-on-yea...

firstwordpharma.com
2
984
Brainomix's AI software flags potential responders to Remedy's stroke drug firstwordpharma.com/story/83…
Brainomix's AI software flags potential responders to Remedy's stroke drug

Brainomix's AI software flags potential responders to Remedy's stroke drug

A post-hoc analysis of a Phase III stroke trial suggests Brainomix's AI-powere...

firstwordpharma.com
2
3
823
Geron's Rytelo expansion bid falters in Phase III myelofibrosis trial $GERN $BMY firstwordpharma.com/story/83…
Geron's Rytelo expansion bid falters in Phase III myelofibrosis trial

Geron's Rytelo expansion bid falters in Phase III myelofibrosis trial

Geron has discontinued a Phase III trial of Rytelo (imetelstat) in myelofibros...

firstwordpharma.com
762
CEO says Biogen has 'returned to growth' as newer drugs, Apellis drive Q3 beat $BIIB firstwordpharma.com/story/83…
CEO says Biogen has 'returned to growth' as newer drugs, Apellis drive Q3 beat

CEO says Biogen has 'returned to growth' as newer drugs, Apellis drive Q3 beat

Biogen said Wednesday that third-quarter revenues rose 11% year-over-year to $2....

firstwordpharma.com
2
1,347
Bispecific from Genmab's Merus buyout cuts HNSCC mortality risk in half $GMAB firstwordpharma.com/story/83…
Bispecific from Genmab's Merus buyout cuts HNSCC mortality risk in half

Bispecific from Genmab's Merus buyout cuts HNSCC mortality risk in half

Shares in Genmab soared 28% on Wednesday after announcing a clinical win for p...

firstwordpharma.com
6
1,253
Formation Bio unveils $600M fund to back more drug acquisitions firstwordpharma.com/story/83…

Formation Bio unveils $600M fund to back more drug acquisitions

More than two years after reeling in 

firstwordpharma.com
1
4
701
Lilly's retatrutide bests Novo's Ozempic in head-to-head diabetes study $LLY $NVO firstwordpharma.com/story/83…
Lilly's retatrutide bests Novo's Ozempic in head-to-head diabetes study

Lilly's retatrutide bests Novo's Ozempic in head-to-head diabetes study

Eli Lilly announced Wednesday that retatrutide outperformed Novo's GLP-1 recept...

firstwordpharma.com
1
1
3
1,668
GSK's shares take a hit after third-quarter vaccine sales disappoint $GSK firstwordpharma.com/story/83…
GSK's shares take a hit after third-quarter vaccine sales disappoint

GSK's shares take a hit after third-quarter vaccine sales disappoint

Shares in GSK fell more than 6% on Wednesday after the company reported that va...

firstwordpharma.com
2
1,016
Astellas gains option to license Audax's immuno-oncology asset in $1.34B deal firstwordpharma.com/story/83…
Astellas gains option to license Audax's immuno-oncology asset in $1.34B deal

Astellas gains option to license Audax's immuno-oncology asset in $1.34B deal

Astellas Pharma said Tuesday it secured an option to license Audax Biosciences' lead immuno-oncology candidate in a deal worth as much as $1.34 billion.Upon exercising ...

firstwordpharma.com
1
2
1,198
With the retirement of its international head, Lilly will rejigger business structure $LLY firstwordpharma.com/story/83…
With the retirement of its international head, Lilly will rejigger business structure

With the retirement of its international head, Lilly will rejigger business structure

Eli Lilly announced changes to the leadership of its US and international oper...

firstwordpharma.com
2
1,664
Genomate Health, VivaMed seek to revive shelved cancer drugs with AI firstwordpharma.com/story/82…
Genomate Health, VivaMed seek to revive shelved cancer drugs with AI

Genomate Health, VivaMed seek to revive shelved cancer drugs with AI

Genomate Health and VivaMed BioPharma are teaming up to find new uses for exist...

firstwordpharma.com
2
754
Teva picks up new neuro assets in BioXcel's bankruptcy sale $TEVA firstwordpharma.com/story/82…
Teva picks up new neuro assets in BioXcel's bankruptcy sale

Teva picks up new neuro assets in BioXcel's bankruptcy sale

Teva Pharmaceuticals said Tuesday it has successfully acquired BioXcel's neuro...

firstwordpharma.com
1
7
1,651
Enveda, Anthropic take aim at drug-development bottlenecks with Claude firstwordpharma.com/story/83…
Enveda, Anthropic take aim at drug-development bottlenecks with Claude

Enveda, Anthropic take aim at drug-development bottlenecks with Claude

Enveda is teaming up with

firstwordpharma.com
1
3
729
Judge denies Novo's injunction bid to stop Lilly's GLP-1 ads $NVO $LLY firstwordpharma.com/story/82…
Judge denies Novo's injunction bid to stop Lilly's GLP-1 ads

Judge denies Novo's injunction bid to stop Lilly's GLP-1 ads

A US federal judge has rejected Novo's attempt to temporarily block Eli Lilly's ...

firstwordpharma.com
1
930
Load more